13.02.2015 • News

Bayer Working On Post-BMS Structure

Bayer has begun working on a new corporate structure for the life-science businesses that will form the group's nucleus when its plastics division, Bayer MaterialScience (BMS), is spun off.

The new structure is expected to be in place by the beginning of 2016, and management has informed employees it will not entail job cuts.

Plans unveiled in September 2014 call for BMS to be spun off to shareholders in an attempt to reduce cyclicality and maximize returns across the portfolio by concentrating on the higher-margin healthcare and agriculture segments.

At the announcement, CEO Marijn Dekkers said an initial public offering was envisaged within the next 12-18 months.

Bayer's three main divisions HealthCare, CropScience and MaterialScience each have largely autonomous management teams but group management has repeatedly pointed to synergies between businesses in human, animal and plant health.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read